Koene Saskia, Dirks Ilse, van Mierlo Esmee, de Vries Pascal R, Janssen Anjo J W M, Smeitink Jan A M, Bergsma Arjen, Essers Hans, Meijer Kenneth, de Groot Imelda J M
Department of Paediatrics, Radboud Center for Mitochondrial Medicine (RCMM), Radboud University Medical Center, PO BOX 9101, Geert Grooteplein 10, Nijmegen, 6500 HB, The Netherlands.
Donders Center for Neuroscience, Department of Rehabilitation, Pediatric Physical Therapy, Radboud University Medical Center, Nijmegen, The Netherlands.
JIMD Rep. 2017;36:7-17. doi: 10.1007/8904_2016_35. Epub 2017 Jan 17.
Feasible, sensitive and clinically relevant outcome measures are of extreme importance when designing clinical trials. For paediatric mitochondrial disease, no robust end point has been described to date. The aim of this study was to select the domains of daily physical activity, which can be measured by 3D accelerometry, that could serve as sensitive end points in future clinical trials in children with mitochondrial disorders.In this exploratory observational study, 17 patients with mitochondrial disease and 16 age- and sex-matched controls wore 3D accelerometers at the upper leg, upper arm, lower arm and chest during one weekend. Using the raw data obtained by the accelerometers, we calculated the following outcome measures: (1) average amount of counts per hour the sensors were worn; (2) the maximal intensity; (3) the largest area under the curve during 30 min and (4) categorized activities lying, standing or being dynamically active. Measuring physical activity during the whole weekend was practically feasible in all participants. We found good face validity by visually correlating the validation videos and activity diaries to the accelerometer data-graphs. Patients with mitochondrial disorders had significantly lower peak intensity and were resting more, compared to their age- and sex-matched peers.Finally, we suggest domains of physical activity that could be included when measuring daily physical activity in children with mitochondrial disorders, preferably using more user-friendly devices. These include peak activity parameters for the arms (all patients) and legs (ambulatory patients). We recommend using or developing devices that measure these domains of physical activity in future clinical studies.
在设计临床试验时,可行、敏感且具有临床相关性的结局指标极为重要。对于儿童线粒体疾病,迄今为止尚未描述出可靠的终点指标。本研究的目的是选择可通过三维加速度计测量的日常身体活动领域,这些领域可作为未来线粒体疾病患儿临床试验中的敏感终点指标。
在这项探索性观察性研究中,17例线粒体疾病患者以及16例年龄和性别匹配的对照者在一个周末期间在上腿部、上臂、下臂和胸部佩戴三维加速度计。利用加速度计获取的原始数据,我们计算了以下结局指标:(1)传感器佩戴期间每小时的平均计数;(2)最大强度;(3)30分钟内曲线下的最大面积;以及(4)分为躺卧、站立或动态活动的活动类别。在所有参与者中,在整个周末测量身体活动在实际操作上是可行的。通过将验证视频和活动日记与加速度计数据图表进行视觉关联,我们发现了良好的表面效度。与年龄和性别匹配的同龄人相比,线粒体疾病患者的峰值强度显著更低,且休息时间更多。
最后,我们建议在测量线粒体疾病患儿的日常身体活动时可纳入的身体活动领域,最好使用更便于使用的设备。这些领域包括手臂(所有患者)和腿部(能行走的患者)的峰值活动参数。我们建议在未来的临床研究中使用或开发能够测量这些身体活动领域的设备。